Isoleucine
Isoleucine is a small molecule pharmaceutical. It is currently being investigated in clinical studies. It is known to target pituitary adenylate cyclase-activating polypeptide type I receptor, vasoactive intestinal polypeptide receptor 1, vasoactive intestinal polypeptide receptor 2, and secretin receptor.
Download report
Favorite
Events Timeline
Commercial
Clinical
Drug
Target
Variants
Financial
Trends
Safety
Events Timeline
5D
1M
3M
6M
YTD
1Y
2Y
5Y
Max
Events
FDA approval date
EMA approval date
Patent expiration date
Study first post date
Last update post date
Start date
Primary completion date
Completion date
Results first post date
Mock data
Subscribe for the real data
Subscribe for the real data
Commercial
Therapeutic Areas
No data
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
No data
Labels
FDA
EMA
Brand Name | Status | Last Update |
|---|---|---|
| aminosyn ii | New Drug Application | 2025-11-02 |
| aminosyn-pf | New Drug Application | 2025-10-17 |
| asce plus derma signal kit srlv | unapproved drug other | 2021-11-23 |
| clinimix | New Drug Application | 2021-04-13 |
| clinimix e | New Drug Application | 2021-04-13 |
| clinisol | ANDA | 2018-06-01 |
| exoscrt derma signal kit srlv | unapproved drug other | 2021-11-23 |
| exoscrt derma signal srlv vial 1. lyophilized | unapproved drug other | 2024-12-09 |
| exoscrt derma signal srlv vial 2. diluent | unapproved drug other | 2024-12-09 |
| ilevro | New Drug Application | 2025-07-16 |
Show 11 more
Indications
FDA
EMA
No data
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
No data
HCPCS
No data
Clinical
Clinical Trials
177 clinical trials
View more details
Mock data
Subscribe for the real data
Subscribe for the real data
Indications Phases 4
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Fibrosis | D005355 | — | — | — | 1 | 1 | 2 | 1 | 5 |
| Brain diseases | D001927 | — | G93.40 | — | — | — | 1 | 3 | 4 |
| Poisoning | D011041 | EFO_0008546 | T65.91 | — | — | — | 1 | 2 | 3 |
| Liver cirrhosis | D008103 | EFO_0001422 | K74.0 | — | — | 1 | 1 | 1 | 3 |
| Malnutrition | D044342 | EFO_0008572 | E40-E46 | — | — | 1 | 1 | 1 | 3 |
| Drug overdose | D062787 | — | — | — | — | — | 1 | 1 | 2 |
| Liver diseases | D008107 | EFO_0001421 | K70-K77 | — | — | — | 1 | 1 | 2 |
| Hepatic encephalopathy | D006501 | — | K72.91 | — | — | — | 1 | 1 | 2 |
| Blood pressure | D001794 | EFO_0004325 | — | — | — | — | 1 | — | 1 |
Indications Phases 3
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Esophageal neoplasms | D004938 | — | C15 | — | 2 | 3 | — | 8 | 13 |
| Esophageal squamous cell carcinoma | D000077277 | — | — | — | 3 | 2 | — | 1 | 6 |
| Covid-19 | D000086382 | — | U07.1 | 1 | 1 | 1 | — | 4 | 6 |
| Sarcopenia | D055948 | EFO_1000653 | M62.84 | — | — | 1 | — | 4 | 5 |
| Postoperative complications | D011183 | — | — | — | — | 1 | — | 2 | 3 |
| Infections | D007239 | EFO_0000544 | — | — | 2 | 1 | — | 1 | 3 |
| Communicable diseases | D003141 | — | — | — | 2 | 1 | — | 1 | 3 |
| Coronavirus infections | D018352 | EFO_0007224 | B34.2 | — | 1 | 1 | — | — | 1 |
| Ascites | D001201 | — | R18 | — | — | 1 | — | — | 1 |
| Lung neoplasms | D008175 | — | C34.90 | — | — | 1 | — | — | 1 |
Show 2 more
Indications Phases 2
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Squamous cell carcinoma | D002294 | — | — | — | 3 | — | — | 1 | 4 |
| Anastomotic leak | D057868 | — | — | — | 1 | — | — | 3 | 4 |
| Breast neoplasms | D001943 | EFO_0003869 | C50 | — | 1 | — | — | 3 | 4 |
| Carcinoma | D002277 | — | C80.0 | — | 3 | — | — | — | 3 |
| Fatigue | D005221 | — | R53.83 | 1 | 1 | — | — | 1 | 3 |
| Heart failure | D006333 | EFO_0003144 | I50 | 2 | 2 | — | — | — | 3 |
| Non-alcoholic fatty liver disease | D065626 | EFO_0003095 | K75.81 | — | 1 | — | — | 1 | 2 |
| Fatty liver | D005234 | EFO_0003934 | — | — | 1 | — | — | 1 | 2 |
| Muscular atrophy | D009133 | — | — | — | 1 | — | — | 1 | 2 |
| Melanoma | D008545 | — | — | — | 1 | — | — | 1 | 2 |
Show 12 more
Indications Phases 1
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Obesity | D009765 | EFO_0001073 | E66.9 | 1 | — | — | — | 8 | 9 |
| Diabetes mellitus | D003920 | EFO_0000400 | E08-E13 | 1 | — | — | — | 2 | 3 |
| Neoplasms | D009369 | — | C80 | 1 | — | — | — | 1 | 2 |
| Kidney diseases | D007674 | EFO_0003086 | N08 | 1 | — | — | — | 1 | 2 |
| Brain neoplasms | D001932 | EFO_0003833 | C71 | 1 | — | — | — | — | 1 |
| Glioblastoma | D005909 | EFO_0000515 | — | 1 | — | — | — | — | 1 |
| Blood coagulation disorders | D001778 | EFO_0009314 | D68.9 | 1 | — | — | — | — | 1 |
| Hemostatic disorders | D020141 | — | — | 1 | — | — | — | — | 1 |
| Renal insufficiency | D051437 | — | N19 | 1 | — | — | — | — | 1 |
| Parkinson disease | D010300 | EFO_0002508 | G20 | 1 | — | — | — | — | 1 |
Indications Without Phase
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
|---|---|---|---|---|---|---|---|---|---|
| Cerebral palsy | D002547 | — | G80 | — | — | — | — | 18 | 18 |
| Paralysis | D010243 | — | — | — | — | — | — | 8 | 8 |
| Hyperglycemia | D006943 | — | R73.9 | — | — | — | — | 3 | 3 |
| Traumatic brain injuries | D000070642 | — | S06 | — | — | — | — | 3 | 3 |
| Pediatric obesity | D063766 | — | — | — | — | — | — | 3 | 3 |
| Sickle cell anemia | D000755 | EFO_0000697 | D57 | — | — | — | — | 3 | 3 |
| Stroke | D020521 | EFO_0000712 | I63.9 | — | — | — | — | 3 | 3 |
| Hiv infections | D015658 | EFO_0000764 | B20 | — | — | — | — | 3 | 3 |
| Healthy volunteers/patients | — | — | — | — | — | — | — | 3 | 3 |
| Metabolic syndrome | D024821 | EFO_0000195 | E88.810 | — | — | — | — | 2 | 2 |
Show 128 more
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
| Drug common name | Isoleucine |
| INN | isoleucine |
| Description | 2-amino-3-methylpentanoic acid is a branched chain amino acid that consists of 3-methylpentanoic acid bearing an amino substituent at position 2. It is an alpha-amino acid and a branched-chain amino acid. |
| Classification | Small molecule |
| Drug class | — |
| Image (chem structure or protein) |  |
| Structure (InChI/SMILES or Protein Sequence) | CC[C@H](C)[C@H](N)C(=O)O |
Identifiers
| PDB | — |
| CAS-ID | 73-32-5 |
| RxCUI | — |
| ChEMBL ID | CHEMBL1233584 |
| ChEBI ID | 17191 |
| PubChem CID | 791 |
| DrugBank | DB00167 |
| UNII ID | 04Y7590D77 (ChemIDplus, GSRS) |
Target
Agency Approved
No data
Alternate
ADCYAP1R1
ADCYAP1R1
Organism
Homo sapiens
Gene name
ADCYAP1R1
Gene synonyms
NCBI Gene ID
Protein name
pituitary adenylate cyclase-activating polypeptide type I receptor
Protein synonyms
adenylate cyclase activating polypeptide 1 (pituitary) receptor type I, PACAP receptor 1, PACAP type I receptor, PACAP-R1, pituitary adenylate cyclase activating polypeptide 1 receptor type I Hiphop, pituitary adenylate cyclase-activating polypeptide type 1 receptor
Uniprot ID
Mouse ortholog
Adcyap1r1 (11517)
pituitary adenylate cyclase-activating polypeptide type I receptor (P70205)
Variants
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Subscribe for the real data
Additional graphs summarizing 88,521 documents
View more details
Safety
Black-box Warning
Black-box warning for: Aminosyn ii
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
Subscribe for the real data
141,039 adverse events reported
View more details
© 2020-2025 Collaborative Drug Discovery Inc. (CDD) | Terms of Use